Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis.

Kukuy O, Kaplan B, Golderman S, Volkov A, Duek A, Leiba M, Ben-Zvi I, Livneh A.

Clin Exp Nephrol. 2019 Jun;23(6):763-772. doi: 10.1007/s10157-019-01699-5. Epub 2019 Feb 8.

PMID:
30734185
2.

Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).

Duek A, Trakhtenbrot L, Amariglio N, Benyamini N, Zilbershats I, Ganzel C, Shevetz O, Leiba R, Rozic G, Nagler A, Leiba M.

Genes Chromosomes Cancer. 2019 Aug;58(8):516-520. doi: 10.1002/gcc.22738. Epub 2019 Feb 6.

PMID:
30675954
3.

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL.

Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29.

4.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

5.

STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models.

Rozic G, Paukov L, Cohen Z, Shapira I, Duek A, Bejamini O, Avigdor A, Nagler A, Koman I, Leiba M.

Oncotarget. 2018 Jul 31;9(59):31367-31379. doi: 10.18632/oncotarget.25825. eCollection 2018 Jul 31.

6.

Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis.

Leiba M, Jarjoura S, Abboud W, Nagler A, Yahalom R, Duek A, Yarom N.

Oral Dis. 2018 Oct;24(7):1343-1348. doi: 10.1111/odi.12901. Epub 2018 Jul 5.

PMID:
29791070
7.

Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.

Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group.

Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2.

PMID:
29501828
8.

Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.

Shaulov A, Avivi I, Cohen Y, Duek A, Leiba M, Gatt ME.

Amyloid. 2018 Mar;25(1):11-17. doi: 10.1080/13506129.2017.1416350. Epub 2017 Dec 14. Review.

PMID:
29241368
9.

Obesity and related risk of myeloproliferative neoplasms among israeli adolescents.

Leiba A, Duek A, Afek A, Derazne E, Leiba M.

Obesity (Silver Spring). 2017 Jul;25(7):1187-1190. doi: 10.1002/oby.21863. Epub 2017 May 12.

10.

Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients.

Leiba M, Malkiel S, Budnik I, Rozic G, Avigdor A, Duek A, Nagler A, Kenet G, Livnat T.

Blood Cells Mol Dis. 2017 Jun;65:1-7. doi: 10.1016/j.bcmd.2017.03.010. Epub 2017 Mar 25.

PMID:
28365523
11.

Higher body mass index in 16-19 year-old Jewish Adolescents of North African, Middle Eastern and European Origins is a Predictor of Acute Myeloid Leukemia: a cohort of 2.3 million Israelis.

Shamriz O, Leiba M, Levine H, Derazne E, Keinan-Boker L, Kark JD.

Cancer Causes Control. 2017 Apr;28(4):331-339. doi: 10.1007/s10552-017-0863-5. Epub 2017 Mar 3.

PMID:
28258513
12.

The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.

Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, Ribakovsky E, Klein S, Olam D, Weiss L, Wald H, Abraham M, Galun E, Peled A, Nagler A.

Clin Cancer Res. 2017 Apr 1;23(7):1733-1747. doi: 10.1158/1078-0432.CCR-15-2618. Epub 2016 Oct 3.

13.

The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo.

Rozic G, Paukov L, Jakubikova J, Ben-Shushan D, Duek A, Leiba A, Avigdor A, Nagler A, Leiba M.

Oncotarget. 2016 Sep 20;7(38):62572-62584. doi: 10.18632/oncotarget.11539.

14.

Risk of Hodgkin lymphoma according to immigration status and origin: a migrant cohort study of 2.3 million Jewish Israelis.

Levine H, Leiba M, Bar Zeev Y, Keinan-Boker L, Derazne E, Leiba A, Kark JD.

Leuk Lymphoma. 2017 Apr;58(4):959-968. doi: 10.1080/10428194.2016.1220552. Epub 2016 Aug 26.

PMID:
27561882
15.

High Normal Uric Acid Levels Are Associated with an Increased Risk of Diabetes in Lean, Normoglycemic Healthy Women.

Shani M, Vinker S, Dinour D, Leiba M, Twig G, Holtzman EJ, Leiba A.

J Clin Endocrinol Metab. 2016 Oct;101(10):3772-3778. Epub 2016 Aug 17.

PMID:
27533308
16.

Temporomandibular joint involvement in patients with multiple myeloma-a retrospective study.

Abboud W, Yahalom R, Leiba M, Greenberg G, Yarom N.

Int J Oral Maxillofac Surg. 2016 Dec;45(12):1545-1550. doi: 10.1016/j.ijom.2016.06.014. Epub 2016 Jul 1.

PMID:
27377681
17.

Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?

Leiba M, Duek A, Amariglio N, Avigdor A, Benyamini N, Hardan I, Zilbershats I, Ganzel C, Shevetz O, Novikov I, Cohen Y, Ishoev G, Rozic G, Nagler A, Trakhtenbrot L.

Genes Chromosomes Cancer. 2016 Sep;55(9):710-8. doi: 10.1002/gcc.22372. Epub 2016 Jun 24.

PMID:
27152944
18.

Adolescent weight and height are predictors of specific non-Hodgkin lymphoma subtypes among a cohort of 2,352,988 individuals aged 16 to 19 years.

Leiba M, Leiba A, Keinan-Boker L, Avigdor A, Derazne E, Levine H, Kark JD.

Cancer. 2016 Apr 1;122(7):1068-77. doi: 10.1002/cncr.29792. Epub 2016 Feb 22.

19.

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.

Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, Abraham M, Wald H, Galun E, Peled A, Nagler A.

Oncotarget. 2014 Nov 30;5(22):11283-96.

20.

Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al.

Leiba M, Avigdor A.

Br J Haematol. 2015 Feb;168(4):604-5. doi: 10.1111/bjh.13125. Epub 2014 Sep 24. No abstract available.

PMID:
25252030
21.

Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.

Kaplan B, Golderman S, Aizenbud B, Esev K, Kukuy O, Leiba M, Livneh A, Ben-Zvi I.

Am J Hematol. 2014 Sep;89(9):882-8. doi: 10.1002/ajh.23773. Epub 2014 Jun 27.

22.

Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.

Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A.

Br J Haematol. 2014 Sep;166(5):702-10. doi: 10.1111/bjh.12946. Epub 2014 May 26.

PMID:
24861981
23.

Israeli-born offspring of Jewish immigrants of Middle Eastern origin have a lower incidence of multiple myeloma than those of European origin: a cohort study of 746 200 Israeli men followed from late adolescence.

Leiba M, Afek A, Derazne E, Keinan-Boker L, Leiba A, Nagler A, Shamiss A, Kark JD.

Leuk Lymphoma. 2014 Oct;55(10):2290-5. doi: 10.3109/10428194.2013.871276. Epub 2014 Jan 28.

PMID:
24359241
24.

Cytogenetics of extramedullary manifestations in multiple myeloma.

Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G.

Br J Haematol. 2013 Apr;161(1):87-94. doi: 10.1111/bjh.12223. Epub 2013 Feb 1.

PMID:
23368088
25.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.

Billecke L, Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G.

Anticancer Res. 2012 May;32(5):2031-4.

PMID:
22593484
26.

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC.

Br J Haematol. 2012 Jun;157(6):718-31. doi: 10.1111/j.1365-2141.2012.09120.x. Epub 2012 Apr 26.

27.

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.

Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.

Haematologica. 2011 Aug;96(8):1170-9. doi: 10.3324/haematol.2010.029363. Epub 2011 Jun 28.

28.

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.

Blood. 2011 Apr 28;117(17):4409-19. doi: 10.1182/blood-2010-02-267344. Epub 2011 Feb 14.

29.

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.

Shimoni A, Leiba M, Schleuning M, Martineau G, Renaud M, Koren-Michowitz M, Ribakovski E, le Coutre P, Arnold R, Guilhot F, Nagler A.

Leukemia. 2009 Jan;23(1):190-4. doi: 10.1038/leu.2008.160. Epub 2008 Jul 3. No abstract available.

PMID:
18596746
30.

Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis.

Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, Rachmilewitz EA.

Br J Haematol. 2008 Aug;142(4):669-71. doi: 10.1111/j.1365-2141.2008.07225.x. Epub 2008 May 21. No abstract available.

PMID:
18498424
31.

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A.

Clin Cancer Res. 2008 May 15;14(10):3044-51. doi: 10.1158/1078-0432.CCR-07-4079.

32.

Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.

Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H.

Differentiation. 2008 Oct;76(8):908-22. doi: 10.1111/j.1432-0436.2008.00270.x. Epub 2008 Apr 29.

PMID:
18452548
34.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC.

Blood. 2008 Aug 15;112(4):1329-37. Epub 2007 Sep 28.

35.

Effect of halofuginone, a collagen alpha1(I) inhibitor, on wound healing in normal and irradiated skin: implication for hematopoietic stem cell transplantation.

Nagler A, Ohana M, Leiba M, Levdansky L, Gorodetsky R.

Acta Haematol. 2007;118(2):77-83. Epub 2007 Jul 4.

PMID:
17622757
36.

Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies.

Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Vlodavsky I, Nagler A.

Leukemia. 2007 Nov;21(11):2296-303. Epub 2007 Jul 5.

PMID:
17611567
37.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.

Blood. 2007 Sep 1;110(5):1656-63. Epub 2007 May 17.

38.

Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis.

Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Livneh A.

Scand J Rheumatol. 2007 Jan-Feb;36(1):48-52.

PMID:
17454935
39.

Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors.

Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A.

Acta Haematol. 2007;117(2):68-73. Epub 2006 Nov 9.

PMID:
17106189
40.

Characterization of HPSE gene single nucleotide polymorphisms in Jewish populations of Israel.

Ostrovsky O, Korostishevsky M, Levite I, Leiba M, Galski H, Gazit E, Vlodavsky I, Nagler A.

Acta Haematol. 2007;117(1):57-64. Epub 2006 Nov 8.

PMID:
17095861
41.

Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.

Leiba M, Cahalon L, Shimoni A, Lider O, Zanin-Zhorov A, Hecht I, Sela U, Vlodavsky I, Nagler A.

J Leukoc Biol. 2006 Aug;80(2):399-406. Epub 2006 Jun 12.

PMID:
16769768
42.

Behcet's Disease: Current Therapeutic Perspectives.

Leiba M, Ehrenfeld M.

Curr Treat Options Cardiovasc Med. 2005 Jun;7(2):139-148.

PMID:
15935122
43.

Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis.

Raanani P, Trakhtenbrot L, Rechavi G, Rosenthal E, Avigdor A, Brok-Simoni F, Leiba M, Amariglio N, Nagler A, Ben-Bassat I.

Acta Haematol. 2005;113(3):181-9.

PMID:
15870488
44.

Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.

Leiba M, Seligsohn U, Sidi Y, Harats D, Sela BA, Griffin JH, Livneh A, Rosenberg N, Gelernter I, Gur H, Ehrenfeld M.

Ann Rheum Dis. 2004 Nov;63(11):1445-9.

45.
46.

Extensive diverticulosis of the small intestine.

Leiba M, Konen E, Sidi Y.

Isr Med Assoc J. 2003 Oct;5(10):756. No abstract available.

47.

Behçet's disease and thrombophilia.

Leiba M, Sidi Y, Gur H, Leiba A, Ehrenfeld M.

Ann Rheum Dis. 2001 Dec;60(12):1081-5. Review. No abstract available.

48.

Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients.

Keidar S, Oiknine J, Leiba A, Shapira C, Leiba M, Aviram M.

J Cardiovasc Pharmacol. 1996 Feb;27(2):183-6.

PMID:
8720415
49.

Giant tumoral calcinosis demonstrated by bone scintigraphy.

Hardoff R, Rudoy J, Gips S, Leiba M, Ben-Ari J.

Clin Nucl Med. 1991 Apr;16(4):279-80. No abstract available.

PMID:
2044323
50.

Intraperitoneal phosphate administration in hungry bone syndrome.

Frajewicki V, Kohan R, Abu-Ata M, Leiba M, Cohen O, Ben-Ari J.

Clin Nephrol. 1990 Nov;34(5):223-4.

PMID:
2176580

Supplemental Content

Support Center